Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College ...
November 16 2017 - 4:05PM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced that data from the Company’s Phase 2 study of NSI-189 in
patients with major depressive disorder will be presented at the
56th American College of Neuropsychopharmacology (ACNP) Annual
Meeting, which is being held in Palm Springs, California from
December 3-7, 2017.
Poster presentation details are as follows:
Title: A Phase 2, Double-Blind,
Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic
Compound Among Out-Patients with Major Depressive
DisorderAbstract Number: M79Session
Title: Poster Session IPresenter: George
Papakostas, M.D., Massachusetts General HospitalDate and
Time: Monday, December 4, 2017, 5:30 PM – 7:30 PM PT
About Neuralstem Neuralstem is a clinical-stage
biopharmaceutical company developing novel treatments for nervous
system diseases of high unmet medical need. NSI-189 is a small
molecule in clinical development for major depressive disorder
(MDD) and in preclinical development for Angelman syndrome,
irradiation-induced cognitive impairment, Type 1 and Type 2
diabetes, and stroke.
NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, chronic spinal cord injury (cSCI) and
Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified
portfolio of product candidates is based on its proprietary neural
stem cell technology.
Cautionary Statement Regarding Forward Looking
InformationThis news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and Form 10-Q for the three and nine
months ended September 30, 2017, filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Contact:
Kimberly MinarovichArgot Partners (Investor
Relations)212-600-1902kimberly@argotpartners.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024